|
|
|
Eleonora Simeoni
|
|
|
office(s):
AI3137
phone(s): [+41 21 69] 31693
|
|
|
MISSION
|
Gene therapy in bone regeneration
Protein/DNA delivery to antigen presenting cell (vaccines development)
|
|
BIOGRAPHY
|
1994
Degree in Biological Sciences with mention outstanding, Virology Institute, University “La Sapienza”, Rome, Italy. Thesis title: “Isolation and biological-molecular characterization of HIV-1 resistant strains to the protease inhibitor Ro31-8959”.
1994-1998
Ph.D. and post-doc, Virology Institute, University “La Sapienza”, Rome, Italy
Research projects: “In vitro and in vivo studies on immuno-biological characteristics of IFN alpha” , “Clinical relevance of anti-Interferon antibodies”, and “Cellular drug-resistance in anti-retroviral treatments”.
1999
Post-doc, CHUV, Lausanne, Switzerland.
Research project: “Evaluation of the CD4+ T cell response to recall antigens in HIV-infected subjects under antiretroviral therapy”.
2000-2005
University assistant, CHUV, Lausanne, Switzerland.
Research projects: “Lentiviral and adenoviral gene therapy in heart transplantation” and “Polymorphism of chemokines and their receptors in the context of atherosclerosis, diabetes, and heart transplantation.
2005
Junior project manager (HIV vaccine program); Mymetics Corporation, Nyon, Switzerland (double affiliation with the CHUV).
PUBLICATIONS
Dianzani F, Antonelli G, Turriziani O, Riva E, Simeoni E, Signoretti C, Strosselli S, Cianfriglia M. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Research and Human Retroviruses, 10: 1467, 1994.
Antonelli G, Giannelli G, Currenti M, Simeoni E, Milella M, Schiraldi O, Dianzani F. Fate of antibodies to interferon (IFN) in chronic Hepatitis C patients treated with recombinant IFN alpha2 and retreated with lymphoblastoid IFN alpha. Int Hep Comm, 4: 232, 1995.
Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F. Antibodies to interferon (IFN) in Hepatitis C patients relapsing while continuing recombinant IFN Beta2 therapy. Clin Exp Immunol, 104: 384, 1996.
Viscomi GC, Antonelli G, Bini L, De Pisa F, Pallini V, Scapol L, Simeoni E. Monoclonal antibodies for the immunological characterization of different pharmaceuti¬cal preparations of interferon alpha. Proceedings of the third pharma analysis Europe, London, 21-22 Oct 1996.
Simeoni E, Dianzani F, Viscomi G, De Pisa F, Colizzi V, Giannelli G, Antonelli G. Clinical relevance of antibodies to IFN in hepatitis C patients. Pharmaceutical Sciences, 3: 43, 1997.
Antonelli A, Simeoni E, Currenti M, De Pisa F, Colizzi V, Pistello M, Dianzani F. Interferon antibodies in patients with infectious disease. Biotherapy, 10: 7, 1997.
Antonelli G, Simeoni E, Artini M, Turriziani O, Dianzani F. Pharmacokinetics of recombinant interferon (IFN)-alpha in a hepatitis patient with neutralizing antibody to IFN. Hepatol Res, 8: 149, 1997.
Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, De Pisa F, Fieschi C, Gasperini C, Salvetti M, Dianzani F. Development of Neutralizing Antibodies in patients with Relapsing-Remitting Multiple Sclerosis treated with IFN beta-1b. J Interferon Cytokine Res, 18: 345, 1998.
Turriziani O, Simeoni E, Antonelli G, Dianzani F. Anti-HIV antiviral activity of stavudine in a thymidine kinase deficient cellular line. Antivir Ther, 3: 191, 1998.
Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzani F. Correlation of interferon-induced expression of MxA mRNA in peripheral mononuclear cells with the response of patients with chronic active hepatitis C to IFN alpha therapy. J Interferon Cytokine Res, 19: 243, 1999.
Viscomi GC, Antonelli G, Bruno C, Scapol L, Malavasi F, Funaro A, Simeoni E, Petska S, De Pisa F, Dianzani F. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN alpha by monoclonal antibodies. J Interferon Cytokine Res, 19: 319, 1999.
Antonelli G, Riva E, Maggi F, Vatteroni ML, Simeoni E. Influence of Hepatitis C Virus (HCV) genotype, HCV RNA Load, and Alanine Aminotransferase level on reduction of HCV RNA after a single administration of Interferon-alpha. J Infect Dis, 180: 1411, 1999.
Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Gasperini C, Fieschi C, Dianzani F. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in Relapsing-Remitting Multiple Sclerosis patients treated with IFN beta-1a or IFN beta-1b. J. Neurol Sci, 168: 131, 1999.
Fleury S, Rizzardi GP, Chapuis A, Tambussi G, Knabenhans C, Simeoni E, Meuwly E, Corpataux JY, Lazzarin A, Miedema F, Pantaleo G. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy (HAART). PNAS, 97: 5393, 2000.
Fleury S, Simeoni E, Zuppinger C, Déglon N, Kappenberger L, Vassalli G. Multiply attenuated, self-inactivating Lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation, 107: 2375, 2003.
Fleury S, Driscoll R, Simeoni E, Dudler J, von Segesser Ludwig K, Kappenberger L, Vassalli G. Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. Basic Res Cardiol, 99: 247-, 2004.
Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, März W, Vassalli G. Association of RANTES G–403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J, 25: 1438, 2004.
Simeoni E, Hoffmann MM, Winkelmann BR, Ruiz J, Fleury S, März W, Vassalli G. Association of monocyte chemoattractant protein-1 (MCP-1) A-2518G gene polymorphism with insuline resistance and type II diabetes mellitus. Diabetologia, 47: 1574, 2004.
Cefai D, Simeoni E, Ludunge KM, Driscoll R, von Segesser LK, Kappenberger L, Vassalli G. Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo. J Mol Cell Cardiol, 38: 333-344, 2005.
Simeoni E, Vassalli G, Seydoux C, Ramsay D, Noll G, von Segesser LK, Fleury S. CCR5, RANTES and CX3CR1 polymorphisms: possible genetic links with acute heart rejection. Transplantation, 80: 1309-1315, 2005.
Simeoni E, Vassalli G, Li J, Fleury S. Lentiviral gene transfer of the chemokine antagonist RANTES 9-68 prolongs heart graft survival. Transplantation, 81: 240-3246, 2006.
Li J, Simeoni E, Fleury S, Dudler J, Fiorini E, Kappenberger L, von Segesser LK, Vassalli G. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg., in press.
Fleury S, Li J, Simeoni E, Dudler J, Fiorini E, von Segesser LK, Kappenberger L, Vassalli G. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther, in press.
Li J, Simeoni E, Fleury S, Alexander AM, Takikawa O, von Segesser LK, Kappenberger L, Trucco M, Vassalli, G. Gene transfer of the tryptophan-catabolizing enzyme indoleamine 2, 3-dioxygenase prolongs survival of rat cardiac allografts. Am J Transplant, manuscript under revisions.
Simeoni E, Dudler J, Fleury S, Li J, Emma Fiorini, Kappenberger L, von Segesser Ludwig K, Vassalli G. Gene Transfer of a novel IL-1 inhibitor, soluble IL-1 type 2 receptor-Ig, improves cardiac allograft survival in rats. Submitted to Basic Res Cardiol.
Dudler J, Simeoni E, Fleury S, Li J, Kappenberger L, von Segesser Ludwig K, Vassalli G. Gene transfer of IL-18 binding protein attenuates cardiac allograft rejection. Submitted to Transpl Int.
|
|
|
Scientist